Caricamento...
Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma
Angiogenesis inhibitors targeting the VEGF signaling pathway have been US FDA approved for various cancers including glioblastoma (GBM), one of the most lethal and angiogenic tumors. This has led to the routine use of the anti-VEGF antibody bevacizumab in recurrent GBM, conveying substantial improve...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Future Medicine Ltd
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3673744/ https://ncbi.nlm.nih.gov/pubmed/23750318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns.12.36 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|